CA
NZ
UK
AU
IND
US
Pure Health Clinics has initiated a series of weekly seminars aimed at educating residents about the nuances of stem cell therapy and regenerative medicine. This new educational drive is strategically positioned to provide clear insights into how regenerative treatments can serve as alternatives to …
STERIS plc (STE) reported a decline of 4.9% in its stock price over the past year, contrasting sharply with the S&P 500's notable increase of 18.7%. This wider market context sets a challenging backdrop for STERIS, impacting investor sentiment and raising questions about the …
The event will include discussions led by the finance chief and the vice president of investor relations, likely focusing on the company's strategic direction and financial health. This conference takes place as Stryker (NYSE: SYK) faces notable stock market pressure, reflected by a recent …
Boston Scientific's operational integrity is under threat as a significant cyberattack has compromised its ability to ship medical products, causing a 3.5% drop in shares. Investors are closely monitoring the situation as delays in the company's supply chain could hinder its performance in the …
Covalon Technologies Ltd. opened its Q3 2026 earnings call on August 27 without yet addressing the operating and financial detail that typically moves the stock. The session began with introductions and procedural framing from management, leaving the substantive discussion of revenue, margins or segment …
Biohaven Ltd. (NYSE: BHVN), a biotechnology firm with a marketCapitalizationof $2.2 billion, is facing someVolatilityin its stock price after announcing the completion of its licensing agreement for Opakalim, a treatment for refractory focal epilepsy. Despite the completion of this critical deal valued at $350 …
Argenx shares surged more than 20% after the drugmaker disclosed that Vyvgart Hytrulo cleared a Phase 3 trial in autoimmune myositis, a disease category with roughly 100,000 diagnosed patients in the United States and no targeted therapies currently approved. The Alkivia study, which combined …
Therapeutic cancer vaccines were, until recently, a loosely bunched field of similarly staged developers running comparable trials on a shared mRNA premise. That is no longer an accurate description. One well-funded developer has been through bankruptcy court. Another has been fully absorbed into a …
VolitionRx (NYSE American:VNRX) is pressing to convert years of research into commercial reality, and a string of August 2026 announcements has put its Nu.Q epigenetics platform back in the spotlight. The diagnostics company, which develops blood-based tests built around nucleosome measurement, highlighted new clinical …
Please wait processing your request...